Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Technical420 Site Search

Returned 71 result(s).

Tryp Therapeutics Announces Q2 2021 Financial Results

Tryp Therapeutics Inc. (CSE: TRYP), today announced its interim financial results for the three and six month periods ended February 28, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the…

Numinus Wellness Is Taking Strides To Advance Its R&D Business Unit

The psychedelic therapy market is one of the most exciting emerging industries and is a vertical that we have been highly focused on. We expect 2021 to be a transformational year for the psychedelic sector as companies prepare to report Phase 3 clinical trial data. We expect positive phase 3…

6 Psychedelic Clinical Trials That Could Have A Major Impact On The Way We Address Mental Health

The psychedelic therapy market is one of the most exciting emerging industries and is a vertical that we are bullish on. The COVID pandemic has put a major emphasis on the value of mental health and we expect the psychedelic therapy industry to gain from this recognition. During the last…

Psyched Wellness Announces New OTCQB Ticker: PSYCF

Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that FINRA accepted its proposed symbol change for the OTCQB market from the former DCNPF to PSYCF. The Company's shares have commenced trading in…

Pure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction Platform

Last month, we published an article that highlighted Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) as an attractive play on the cannabis and psychedelic extract market. Our thesis is based off the strength of the management team, the structure of the business, and the potential catalysts for…

Psyched Wellness’ Mycological Research Continues To Take Serious Strides Forward

In late December, Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) reported to have started to research the impact that muscimol has on a variety of ailments and we are impressed with how the story has advanced since then. Less than two weeks after Psyched announced that it started…

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Cybin Inc. (NEO:CYBN), a life sciences company focused on psychedelic therapeutics, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel to leverage its innovative technology, Kernel Flow, for its upcoming sponsored clinical work. Click here to view the accompanying film. Flow is a…

Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products

Numinus Wellness Inc.  (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), announced today that it has signed a lab services agreement with Optimi Health Corp., developers of a vertically integrated functional mushroom brand focused…

Mindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of Potential Clinical Use Cases Including Micro-Dosing

Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that certain compounds belonging to its third family of patent-pending next generation psychedelic compounds…

Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC

Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC, a psychiatric clinic platform focused on the administration of psychedelic-assisted therapy to treat mental health disorders. Entheon has…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link